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were updated to € 2013. Results: The primary analysis compared dapagliflozin 
with sulfonylureas resulting in 0.525 additional QALYs and € 1,835 additional cost 
(cost-effectiveness ratio of € 3,496/QALY). The higher drug cost of dapagliflozin was 
partially offset by lower costs of complications, hypoglycemia and the cost associ-
ated with weight gain. In the secondary analyses, dapagliflozin was a cost-effective 
option compared with thiazolidinediones and DPP4, resulting in a cost per QALY 
gained of € 20,183 and € 487, respectively. The univariate and probabilistic sensitivity 
analyses confirmed the robustness of the results. ConClusions: Dapagliflozin in 
combination with metformin proved to be a cost-effective alternative compared to 
sulfonylureas, thiazolidinediones and DPP4 inhibitors in the treatment of T2DM.
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objeCtives: Diabetes is a chronic disease and associated with significant health 
care expenditures. Increasing costs are mainly related to long-term complications. 
Identifying patterns of hypoglycemia by means of a blood glucose monitoring sys-
tem (BGMS) can be used to support diabetes management efficiently. Methods: 
An economic analysis was carried out to estimate the life-time cost-effectiveness 
(CEA) of blood glucose monitoring system (BGMS) with pattern alert technology vs. 
standard BGMS for the prevention of Severe Hypoglycaemia (SH) in insulin-treated 
type 1 (DM1) and type 2 patients (DM2). The cost-effectiveness analysis was based 
on a literature review and cost data (direct and indirect) from the Emilia Romagna 
region; a decision tree was developed to calculate the incremental cost per addi-
tional quality of life. The BIA (Budget Impact Analysis) estimated the cost of using 
the new pattern alert technology in the Italian Healthcare System. Results: For 
the base-case scenario, the utilization of BGMS with pattern alert technology was 
less costly and more effective compared to standard BGMS. Life time cost savings 
for the prevention of SH were 300 euro for DM1 and DM2 patients using pattern 
alert technology. The difference in life time QALYs was 0,17. ConClusions: BGMS 
with pattern alert technology, monitoring individual blood glucose levels are cost 
effective in preventing SH for DM1 and insulin-treated DM2 patients, as well as in 
detecting blood glucose trends and patterns. Nevertheless, empirical data on the 
probability of reducing Severe Hypoglycemia is necessary in order to reach any 
firm conclusions.
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objeCtives: Diabetes mellitus represents a significant challenge to health care 
providers in Spain, with a national prevalence of over 8% and approximately 20,000 
diabetes-related deaths annually. Treatment with GLP-1 receptor agonists and DPP-4 
inhibitors, which target the incretin axis, has the potential to improve glycemic 
control without the weight gain associated with traditional therapies. To evaluate 
the relative cost-effectiveness of incretin therapies, the present study compared the 
long-term clinical and cost implications associated with liraglutide and sitagliptin in 
type 2 diabetes patients in Spain. Methods: Data were taken from a randomized, 
controlled trial (NCT00700817) in which adults with type 2 diabetes (mean age 55 
years, HbA1c 8.4%, BMI 33kg/m2) failing metformin monotherapy were randomly 
allocated to receive either 1.2mg liraglutide or 100mg sitagliptin daily in addition 
to metformin. Liraglutide was associated with greater improvements from baseline 
HbA1c (–1.24% vs. –0.9%) and BMI (–0.99kg/m2 vs. –0.33kg/m2). Long-term projec-
tions of clinical outcomes and direct costs (2012 EUR) were made using a published 
and validated model of type 2 diabetes and assumed patients switched to insulin 
after five years. Results: Liraglutide was associated with improved life expec-
tancy (14.05 years vs. 13.91 years) and quality-adjusted life expectancy (9.04 quality-
adjusted life years [QALYs] vs. 8.87 QALYs) compared to sitagliptin. Improved clinical 
outcomes were driven by improved glycemic control, leading to a reduced incidence 
of diabetes-related complications, including renal disease, cardiovascular disease, 
ophthalmic and diabetic foot complications. Mean cost savings as a result of avoided 
complications were EUR 1,827 per patient. Overall, liraglutide was associated with 
increased direct costs of EUR 2,297, yielding an incremental cost-effectiveness ratio 
of EUR 13,266 per QALY gained versus sitagliptin. ConClusions: Liraglutide was 
projected to improve life expectancy, quality-adjusted life expectancy and reduce 
incidence of diabetes-related complication. Liraglutide is likely to be cost-effective 
from a health care payer perspective in Spain.
PDB50
heAlth-economIc comPArIson of contInuous suBcutAneous InsulIn 
InfusIon versus multIPle DAIly InjectIons for the treAtment of tyPe 
1 DIABetes In KAzAKhstAn chIlDren
Roze S.1, Demessinov A.2, Zeityn M.2, Toktarova N.3, Abduakhassova G.4, Sissemaliev R.5, 
Karamalis M.6, Dunne N.6, Muratalina A.5, Klots M.6, Lynch P.6
1HEVA HEOR, Lyon, France, 2Republican Centre for Health Development, Astana, Kazakhstan, 
3National Scientific Medical Centre, Astana, Kazakhstan, 4National Scientific Centre of Maternity 
and Childhood, Astana, Kazakhstan, 5Medtronic, Almaty, Kazakhstan, 6Medtronic, Tolochenaz, 
Switzerland
objeCtives: To project the long-term costs and outcomes of continuous subcu-
taneous insulin infusion (CSII) compared with multiple daily injections (MDI) in 
children with Type 1 diabetes in KAZAKHSTAN. Methods: The CORE Diabetes 
Model is a peer-reviewed, validated model, which employs standard Markov/Monte 
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objeCtives: To project the long-term costs and outcomes of continuous sub-
cutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) 
in adult patients with Type 1 diabetes in KAZAKHSTAN. Methods: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
Markov techniques to describe the long-term incidence and progression of diabe-
tes-related complications. It was used to simulate disease progression in a cohort 
of adult patients with baseline characteristics and costs taken from primary data 
collection in KAZAKHSTAN (mean age 39.7 years, duration of diabetes 10.1 years 
and mean HbA1c 8.5%). Clinical outcomes (HbA1c and hypoglycemic events) were 
taken from a published meta-analysis of CSII studies. Direct costs for 2013 were 
calculated from a third-party payer perspective. Discount rates of 5% per annum 
were applied to costs and 3% to clinical outcomes. Results: Treatment with CSII 
was associated with an improvement in mean quality adjusted life expectancy 
(QALE) of 0.745 years compared with MDI and incidence of any diabetes related 
complication was delayed on average by 1 year with CSII. This produced an incre-
mental cost-effectiveness ratio (ICER) of KZT 4’784’971 per quality-adjusted life 
year (QALY) gained with CSII vs. MDI. CSII related therapy costs were partially 
offset by the savings due to the reduction in long-term complications. CSII treat-
ment also delayed the average onset of complications such as ESRD (1.9 years) and 
blindness (2.1 years). Extensive sensitivity analyses showed the robustness of the 
results. ConClusions: Improvements in glycemic control associated with CSII 
over MDI led to improved QALE owing to reduced incidence of diabetes-related 
complications. CSII was associated with ICERs representing good value for money 
by current standards in KAZAKHSTAN (using a WTP threshold of 6,330,000 KZT 
[3x GDP]) from a payer’s perspective. CSII would be even more attractive from a 
societal perspective when including indirect costs.
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objeCtives: Dapagliflozin (DAPA), a selective SGLT2 inhibitor, reduces hypergly-
caemia in an insulin-independent manner by increasing urinary glucose excretion. 
Glipizide (sulphonylurea) reduces hyperglycemia by increasing beta cell insulin 
secretion. We conducted an analysis of the cost of treating patients to a clinically 
relevant composite endpoint of HbA1c < 7%, no major or minor hypoglycaemic 
events and weight loss ≥ 3%. Methods: The Cardiff Diabetes model was used to 
estimate the cost of treating patients to the composite endpoint of HbA1c < 7%, 
no major or minor hypoglycaemic events and weight loss ≥ 3% in the UK using 
52 week data from a previously published double-blind randomised clinical trial 
of DAPA vs glipizide (GLIP) in combination with metformin (NCT 00660907). The 
cost of treating one patient to the composite endpoint using DAPA or GLIP over 
52 weeks was calculated as total cost per treatment arm divided by number of 
patients that reached the composite endpoint in that treatment arm. Calculation 
of costs included drug acquisition costs, cost for adverse events, and costs related 
to the patient’s BMI level. Results: The number needed to treat was 5 on DAPA 
and 54 on GLIP for one patient to achieve the composite endpoint. The overall cost 
of treating one patient over 52 weeks to the composite endpoint of HbA1c < 7%, no 
major or minor hypoglycaemic events and ≥ 3% weight loss was £3296 on DAPA 
and £13620 on GLIP. ConClusions: The cost of treating one patient to composite 
endpoint of HbA1c < 7%, no major/minor hypoglycaemic events and ≥ 3% weight 
loss was approximately 4 times higher with GLIP compared to DAPA. These results 
demonstrate that when multiple treatment goals, including weight loss and reduc-
tion of hypoglycaemic events are targeted, the cost of treating patients with DAPA 
is lower compared to GLIP.
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objeCtives: To analyse the cost-effectiveness of dapagliflozin in combination with 
metformin in the treatment of type 2 diabetes (T2DM) in comparison with sulfo-
nylureas, thiazolidinediones and DPP4 inhibitors also combined with metformin 
in Spain. Methods: The analysis was based on the results of the available clinical 
trials in order to estimate the quality-adjusted life years (QALY) and economic con-
sequences of managing the disease and its complications. An economic model was 
used to simulate the natural history of 10,000 T2DM patients with each treatment 
option. The analysis was performed from the National Health System perspective 
considering direct costs (pharmacological costs, adverse events, T2DM complica-
tions, hypoglycaemias and costs related to weight gain) and patient’s entire life 
as time horizon. A discount rate of 3% was applied to costs and benefits. All costs 
